undamentalytics Newsletter
Sign in

Inventiva S.a. revenue

Inventiva S.a.'s revenue was $5.1m in fiscal 2025, down 49.1% on the year before. Since fiscal 2018 ($3.8m) it has grown at a compound 4.3% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue48051319105
Growth on the year before—+107.4%−94.6%+>999%+158.6%+47.3%−47.4%−49.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Inventiva S.a. $5.1m -49.1% —
Adlai Nortye Group Ltd. $5.0m — —
Immuron Ltd $5.2m 10.9% —
Rani Therapeutics Holdings, Inc. $4.9m 306.4% —
Bolt Biotherapeutics, Inc. $4.7m 12.8% —
Entrada Therapeutics, Inc. $4.7m -94.1% —

Compare with peers

Head to head: ANL vs IVAIMRN vs IVAIVA vs RANI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inventiva S.a.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inventiva S.a.